Mascoma Corporation

Flagship Highlighted in CNBC Article on Green Technology

Flagship Highlighted in CNBC Article on Green Technology

February 13, 2007

Flagship General Partner Jim Matheson was recently interviewed and quoted in a CNBC web article about Venture Capital invesment in technolgies for alternative energy, which also highlights portfolio company Mascoma.

Green Technology Revs Up Venture Capitalists
By Scott Reeves | 13 Feb 2007 | 03:09 PM
cnbc.com

© 2007 CNBC, Inc. All Rights Reserved

The smart money sees a green future in alternative technology.

Black Duck Software, Inc.

Black Duck Software Closes $12 Million in Third Round Financing

Black Duck Software Closes $12 Million in Third Round Financing

February 14, 2007

Software Compliance Management Visionary and Provider of Industry’s Most Widely Used Solutions Raises Funds to Power Global Expansion, Further Broaden Product Line

LS9

LS9 Launched to Create Renewable Petroleum(TM) Biofuels

LS9 Launched to Create Renewable Petroleum(TM) Biofuels

February 14, 2007

Academic and Industry Leaders Pursue Industrial Applications of Synthetic Biology

BG Medicine, Inc.

Critical Path Liver Toxicity Biomarker Study to Commence with Participation from Seven Pharmaceutical Companies

Critical Path Liver Toxicity Biomarker Study to Commence with Participation from Seven Pharmaceutical Companies

February 21, 2007

Pre-Clinical Study Aims to Predict Human Toxicity

Adnexus Therapeutics

Bristol-Myers Squibb Company and Adnexus Therapeutics Announce Collaboration to Develop and Commercialize Innovative Oncology Compounds

Bristol-Myers Squibb Company and Adnexus Therapeutics Announce Collaboration to Develop and Commercialize Innovative Oncology Compounds

February 26, 2007

Companies To Leverage Adnexus' Proprietary Adnectin-PROfusion Product Engine For Advanced Biologics

Princeton, NJ and Waltham, MA, February 26, 2007 -- Bristol-Myers Squibb Company (NYSE:BMY) and Adnexus Therapeutics today announced a worldwide strategic alliance to discover, develop and commercialize Adnectin-based therapeutics for important oncology-related targets.

Helicos BioSciences Corporation

Helicos BioSciences Files Registration Statement for Initial Public Offering of Common Stock

Helicos BioSciences Files Registration Statement for Initial Public Offering of Common Stock

February 28, 2007

CAMBRIDGE, MASS., February 28 /CNW/ - Helicos BioSciences Corporation today announced it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of its common stock. All of the shares to be offered will be sold by the company. The number of shares to be sold in the proposed offering and the offering price have not yet been determined.

Mascoma Corporation

Royal Nedalco Signs Agreement to License Technology to Mascoma for Lignocellulosic Ethanol

Royal Nedalco Signs Agreement to License Technology to Mascoma for Lignocellulosic Ethanol

March 2, 2007

American – Dutch Technology Partnership to Explore Collaborative Research to Accelerate Commercialization of Lignocellulosic Ethanol

VisEn Medical, Inc.

VisEn Medical Announces Initiative with Merck to Develop Molecular Imaging Agents for Key Areas in Cardiovascular Disease

VisEn Medical Announces Initiative with Merck to Develop Molecular Imaging Agents for Key Areas in Cardiovascular Disease

March 6, 2007

Woburn, MA -- March 6, 2007 –VisEn Medical today announced the launch of a multi-year joint research and development program with Merck & Co., Inc. to develop and apply a range of fluorescence imaging agents for real-time imaging of key disease biomarkers in vivo.

LS9

Renewable Petroleum Company LS9 Announces Series A Funding and Scientific Advisory Board Members

Renewable Petroleum Company LS9 Announces Series A Funding and Scientific Advisory Board Members

March 12, 2007

Company Positioned for Biofuel Breakthroughs and Commercialization

Pervasis Therapeutics, Inc.

Pervasis Therapeutics Launches Enrollment for Two Phase II Clinical Trials for Vascugel™

Pervasis Therapeutics Launches Enrollment for Two Phase II Clinical Trials for Vascugel™

March 19, 2007

Pioneer in regenerative cell-based therapies and devices kicks off patient recruitment for Phase II clinical safety trials of first biologically-active treatment to ameliorate acute vascular injury in multiple disease states

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pervasis Therapeutics, Inc., a pioneer in regenerative cell-based therapies and devices, today announced that it has begun enrolling patients in two Phase II clinical trials of the company’s first product, Vascugel™.